1. Introduction {#sec1-biomolecules-09-00834}
===============

Post-traumatic stress disorder (PTSD) is a trauma- and stressor-related disorder \[[@B1-biomolecules-09-00834]\] that develops in a portion of individuals who show distress and functional impairment after experiencing or witnessing a traumatic event. PTSD symptom clusters include re-experiencing, avoidance, negative thoughts, negative mood, and hyperarousal \[[@B1-biomolecules-09-00834]\]. The prevalence of PTSD differs according to differences in trauma exposure and trauma types worldwide and can be regionally specific. Combat and war-related traumas are associated with 11--20% prevalence in United States combat veterans \[[@B2-biomolecules-09-00834]\], whereas in Croatian combat exposed veterans, the estimated prevalence of PTSD ranges from 14 to 40% \[[@B3-biomolecules-09-00834]\]. PTSD is associated with different somatic comorbidities such as metabolic syndrome, increased inflammatory processes, pulmonary, cardiovascular and autoimmune diseases \[[@B4-biomolecules-09-00834],[@B5-biomolecules-09-00834],[@B6-biomolecules-09-00834],[@B7-biomolecules-09-00834]\], and it is recognized as systemic disease \[[@B8-biomolecules-09-00834]\]. Due to its complex etiology, the biological underpinning of PTSD is still not clear, validated and clinically useful biomarkers have not been identified, and various potential suggested biomarkers were not replicated \[[@B9-biomolecules-09-00834]\].

N-glycans are complex carbohydrate chains linked by N-glycosidic bonds to various proteins or lipids. Glycosylation is a post-translational modification that affects diverse protein functions such as cell adhesion, signal transduction, receptor activation, molecular trafficking, and systemic clearance \[[@B10-biomolecules-09-00834]\]. N-glycans affect different cellular processes and biological functions \[[@B11-biomolecules-09-00834]\]. Altered glycosylation in plasma, serum, and cerebrospinal fluid (CSF) is found in cancer, autoimmune, infectious and chronic inflammatory diseases \[[@B11-biomolecules-09-00834],[@B12-biomolecules-09-00834]\] and aging \[[@B12-biomolecules-09-00834],[@B13-biomolecules-09-00834],[@B14-biomolecules-09-00834]\]. N-glycans attached to IgG, constituting 10--20% of plasma proteins, have been associated with the pathogenesis and progression of different diseases, and biological age \[[@B12-biomolecules-09-00834]\]. Beside these somatic disorders, changes in plasma, serum and CSF glycosylation patterns were found in different neuropsychiatric diseases, such as schizophrenia \[[@B15-biomolecules-09-00834]\], major depressive disorder (MDD) \[[@B16-biomolecules-09-00834]\], attention-deficit hyperactivity disorder (ADHD) \[[@B17-biomolecules-09-00834]\], dementia \[[@B14-biomolecules-09-00834]\] and Alzheimer's disease (AD) \[[@B18-biomolecules-09-00834]\]. To date, only one study evaluated 9 N-glycan structures and accelerated aging in a small number of trauma exposed subjects \[[@B19-biomolecules-09-00834]\]. An association between particular protein glycosylation in highly stressed groups, such as in professional soldiers was detected in earlier study \[[@B20-biomolecules-09-00834]\]. Although the authors did not use highly specific and robust N-glycosylation profiling, they reported a significantly higher concentration of the highly-sialylated glycoprotein stressin whose concentration was positively correlated with stress intensity \[[@B20-biomolecules-09-00834]\].

PTSD is a severe disorder that significantly impairs normal functioning and quality of life of affected persons and their families \[[@B9-biomolecules-09-00834]\]. Therefore, better understanding of the biological basis of PTSD is extremely important. The exact biological factors associated with vulnerability or resilience to PTSD are still unknown, but vulnerability is presumably the result of the complex interplay between environmental, biological, and genetic factors. Clinically useful and validated biomarkers of PTSD, that will enable insight into the biological alterations in PTSD, are missing \[[@B9-biomolecules-09-00834]\]. N-glycans are usually considered as mediators between environmental stimuli and genetic background that are highly responsible for crucial physiological processes and are strongly affected by age \[[@B14-biomolecules-09-00834]\], sex \[[@B21-biomolecules-09-00834]\], and ethnicity \[[@B22-biomolecules-09-00834]\]. Therefore, the aim of this study was to compare the N-glycosylation profile between war veterans with PTSD and age-, sex-, and ethnicity- matched healthy control subjects. The goal of the study was to identify validated and clinically useful biomarkers of PTSD. The hypothesis of this study was that alterations in plasma/IgG N-glycome will be associated with PTSD and/or severity of PTSD symptoms. We also predicted, based on the preliminary results of the accelerated aging in PTSD \[[@B19-biomolecules-09-00834]\] that veterans with PTSD will have higher values on the GlycoAge Test than control subjects, indicating faster aging in PTSD.

2. Methods {#sec2-biomolecules-09-00834}
==========

2.1. Participants {#sec2dot1-biomolecules-09-00834}
-----------------

The study design included two cohorts: discovery and replication, which together comprise 543 age-matched unrelated male Caucasian individuals of Croatian origin: 299 with combat-related PTSD and 244 age-matched control subjects, not exposed to combat trauma. Discovery cohort was enrolled in the period between autumn of 2015 and spring of 2016, whereas the samples for the replication cohort were collected in the period between autumn of 2016 and the spring of 2017. Individuals had current and chronic PTSD, diagnosed using the Structured Clinical Interview (SCID) based on DSM-5 criteria \[[@B1-biomolecules-09-00834]\]. At the time of sampling, individuals with PTSD did not receive psychiatric medication for at least 30 days. Control (*N* = 73) and subjects with PTSD (*N* = 160) in the discovery cohort (*N* = 233) were sampled from October 2015 to January 2016, whereas control (*N* = 171) and subjects with PTSD (*N* = 139) in the replication cohort (*N* = 310) were sampled from October 2016 to February 2017. Individuals with PTSD were 39--77 years old, with exposure to warzone trauma during the Homeland war in Croatia (1991--1995). The median age (25th; 75th percentile) of PTSD patients was 55 (50; 59) and 56 (52; 53) in the discovery and replication cohort, respectively, whereas the median age (25th; 75th percentile) of control subjects was 53 (48; 58) and 57 (49; 63) in the discovery and replication cohort, respectively. The Clinician Administered PTSD Scale (CAPS) \[[@B23-biomolecules-09-00834]\] was used to assess severity of PTSD. According to the CAPS severity, individuals with PTSD were subdivided into those with moderate (range: 66--95 CAPS scores) and severe (range: 96--136 CAPS scores) PTSD symptoms. There were no individuals with mild PTSD symptoms (range: 46--65 CAPS scores). Median number of CAPS scores (25th; 75th percentile) was 86 (78; 88) in the discovery cohort and 85 (78; 86) in the replication cohort. The median BMI (25th; 75th percentile) of healthy control subjects was 27.4 (25.7; 30.0) and 29.0 (27.2; 31.2) in the discovery and replication cohort, respectively; whereas median BMI (25th; 75th percentile) of individuals with PTSD was 27.7 (25.8; 30.3) and 28.1 (25.7; 30.5) in the discovery and replication cohort, respectively.

Exclusion criteria were chronic drug abuse, alcohol dependence or pathophysiological changes in the liver, MDD, schizophrenia, bipolar disorder, adult ADHD, AD, current or recent (previous 3 months) use of lipid lowering agents, antihypertensive, and antidiabetic medication. All participants were additionally evaluated according to the International Classification of Diseases (ICD-10) to exclude potential somatic disease such as fibrosis, sclerosis, cirrhosis and malignant liver disease (alcoholic liver cirrhosis (K70.3), alcoholic liver fibrosis and sclerosis (K70.2), and hepatocellular carcinoma (C22.0)) that might affect N-glycan levels.

Healthy control subjects were evaluated with the same diagnostic instruments and followed the same inclusion/exclusion criteria. The aims and procedures of the study were explained in detail to all participants. Written informed consent was obtained from all subjects/patients. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects/patients were approved by the Ethics Committee of the University Psychiatric Hospital Vrapce, Zagreb, Croatia.

2.2. Blood Sampling {#sec2dot2-biomolecules-09-00834}
-------------------

Blood samples were collected between 7:30 and 8:00 a.m., after overnight fasting, using BD Vacutainer™ glass blood collection tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) with acid citrate dextrose (ACD). Immediately after blood sampling, platelet poor plasma was separated by series of centrifugation and stored at −80 °C. Plasma samples, in both cohorts, were randomized and blinded prior to N-glycan determination to avoid bias.

3. N-glycan Determination in Plasma {#sec3-biomolecules-09-00834}
===================================

3.1. Glycan Release and Labelling in Plasma {#sec3dot1-biomolecules-09-00834}
-------------------------------------------

Plasma N-glycans were determined as described previously \[[@B24-biomolecules-09-00834]\]. Plasma samples (10 μL) were mixed with 20 μL of 2% (*w*/*v*) SDS (Invitrogen, Camarillo, CA, USA) for 10 min at 65 °C in order to achieve protein denaturation in the samples, followed by addition of 4% (*v*/*v*) Igepal CA630 (SigmaAldrich, St. Louis, MO, USA) to the mixture. N-glycans were released by digestion with 1.2 U PNGase F (Promega, San Luis Obispo, CA, USA) overnight, at 37 °C. Following extraction, glycans were fluorescently labeled with 2-aminobenzamide (2-AB) after 2 h incubation at 65 °C. To prepare the labeling solution, 2-AB (19.2 mg/mL; SigmaAldrich, St. Louis, MO, USA) and 2-picoline borane (44.8 mg/mL; SigmaAldrich) were dissolved in a mixture of dimethylsulfoxide (SigmaAldrich, St. Louis, MO, USA) and glacial acetic acid (Merck, Darmstadtd, Germany) (70:30 *v*/*v*).

3.2. Hydrophilic Interaction High Performance Liquid Chromatography (HILIC) {#sec3dot2-biomolecules-09-00834}
---------------------------------------------------------------------------

Released glycans were subjected to HILIC, Acquity UPLC instrument (Waters, Milford, MA, USA), on a Waters BEH Glycan chromatography column, 150 × 2.1 mm i.d., 1.7 μm BEH particles at 25 °C with 100 mM ammonium formate adjusted to pH 4.4 (solvent A) and acetonitrile (solvent B). Samples were kept at 10 °C before the injection. The separation was achieved with a linear gradient of solvent A (30--47%) at 0.56 mL/min flow rate, during 23 min long analysis. Runs were performed with fluorescence detector set with excitation and emission wavelengths of 250 and 428 nm, respectively. The system was calibrated using an external standard of hydrolyzed and 2-AB-labeled glucose oligomers from which the retention times for the individual glycans were converted to glucose units. The obtained chromatograms were all separated into 39 chromatographic areas (peaks) and automatic processing method, with a traditional integration algorithm, was used to process the data. The amounts of glycan present in each area were expressed as the percent of total integrated chromatogram and the peaks were assigned as described by Saldova and colleagues \[[@B25-biomolecules-09-00834]\].

4. N-glycan Determination in IgG {#sec4-biomolecules-09-00834}
================================

4.1. Glycan Release and Labelling in IgG {#sec4dot1-biomolecules-09-00834}
----------------------------------------

Plasma samples (50 μL) were diluted 10x with the binding buffer and applied to the Protein G plate. The filtration of the samples was completed in approximately 5 min. The plate was washed five times with 5 column volumes (CV) of binding buffer to remove unbound proteins. IgG was released from the protein G monoliths using 5 CV of elution solvent (0.1 M formic acid, pH 2.5). Eluates were collected in a 96 deep-well plate and neutralized to pH 7.0 with 1 M ammonium bicarbonate to maintain the IgG stability. After each sample application, the monoliths were regenerated with the following buffers: 10 CV of 10× PBS, followed by 10 CV of 0.1 M formic acid and 10 CV of 1× PBS to re-equilibrate the monoliths. Each step of the chromatographic procedure was done under vacuum (cca. 60 mmHg pressure reduction while applying the samples, 500 mmHg during elution and washing steps). The purity of the isolated IgG was verified by SDS-PAGE with NuPAGE Novex 4--12% Bis-Tris gels in an Xcell SureLock Mini-Cell (Invitrogen) according to the manufacturer. Precision Plus Protein All Blue Standards (BioRad, Hercules, CA, USA) were used as the molecular weight markers. The gels were run at 180 V for 45 min, stained with GelCode Blue (Thermo Fisher scientific, Waltham, MA, USA) and visualized by a VersaDoc Imaging System (BioRad, Hercules, CA, USA).

4.2. Ultraperformance Liquid Chromatography (UPLC) Analysis of IgG Glycans {#sec4dot2-biomolecules-09-00834}
--------------------------------------------------------------------------

Fluorescently labelled N-glycans were separated by UPLC on a Waters Acquity UPLC instrument consisting of a quaternary solvent manager, sample manager and a FLR fluorescence detector set with excitation and emission wavelengths of 330 and 420 nm, respectively. The instrument was under the control of Empower 2 software, build 2145 (Waters, Milford, MA, USA). Labeled N-glycans were separated on a Waters BEH Glycan chromatography column, 100 × 2.1 mm i.d., 1.7 μm BEH particles, with 100 mM ammonium formate (pH 4.4) and acetonitrile. The separation method was developed, which uses a linear gradient of 75--62% acetonitrile at a flow rate of 0.4 mL/min in a 20 min analytical run. Samples were maintained at 5 °C prior to injection, and the separation temperature was 60 °C. The system used hydrolyzed and 2-AB labeled glucose oligomers as external standard, from which the retention times for the individual glycans were converted to glucose units. Data processing was performed using an automatic method with a traditional integration algorithm after which each chromatogram was manually corrected to maintain the same intervals of integration for all the samples. The obtained chromatograms were separated into 24 peaks representing percentage of total integrated area as described previously \[[@B14-biomolecules-09-00834]\].

5. Statistical Analysis {#sec5-biomolecules-09-00834}
=======================

To remove experimental variation from measurements, normalization and batch correction were performed on UPLC glycan data. Normalization of raw measurements within each sample is required because intensities of UPLC signals can vary more than 100-fold due to experimental noise. Also, laboratory conditions can vary during the experiment, so correction of batch effects is necessary \[[@B26-biomolecules-09-00834]\]. To make measurements across samples comparable, normalization by total area is performed where peak area of each glycan structure was divided by total area of corresponding chromatogram. Prior to batch correction, normalized glycan measurements were log transformed due to right-skewness of their distributions and multiplicative nature of batch effects. Batch correction was performed on log-transformed measurements using ComBat method \[[@B27-biomolecules-09-00834]\], R package sva \[[@B28-biomolecules-09-00834]\], where technical source of variation (which sample was analyzed on which plate) was modeled as batch covariate. To get measurements corrected for experimental noise, estimated batch effects were subtracted from log-transformed measurements.

The results are expressed as medians and 25th (Q1) and 75th (Q3) percentiles and were evaluated with R Statistics 3.5.1. Normality of the distribution was assessed with the Kolmogorov--Smirnov test. As most of the glycan peaks were not normally distributed, non-parametric analyses were used. The 39 plasma and 24 IgG N-glycans are shown as percentages of the total area under the curve. Besides individual N-glycans in plasma and IgG, GlycoAge index was calculated for each individual. GlycoAge index was determined as a logarithmic ratio of two N-glycan structures that showed the highest changes in concentration depending on age: agalactosylated core-a-1,6-fucosylated biantennary N-glycan (FA2), which concentration increases gradually with age and bigalactosylated core-a-1,6-fucosylated biantennary N-glycan (FA2G2), which concentration decreases with aging (log10(FA2/FA2G2)) \[[@B14-biomolecules-09-00834]\]. Plasma and IgG samples from the PTSD and control group are shown separately for the discovery and the replication study. Multiple linear regression was used to determine the effect of age, BMI and smoking on levels of plasma and IgG N-glycan species. As the age is a main predictor of N-glycosylation changes in human plasma \[[@B29-biomolecules-09-00834]\] and IgG \[[@B30-biomolecules-09-00834]\], correction for the effect of age was performed by fitting the linear model of each glycan peak in dependence of age and using the obtained residuals for further statistical analysis \[[@B19-biomolecules-09-00834]\]. Differences in the distribution of N-glycans and GlycoAge index values between veterans with PTSD and control subjects, and between PTSD severity subgroups were evaluated using Mann-Whitney tests with corrected N-glycan values. Correlations between N-glycans and severity of PTSD were analyzed with Spearman's rank tests. False discovery rate (Benjamini Hochberg) method was used to correct *p* values due to the multiple testing. The corrected values at *p* \< 0.05 were considered significant.

6. Results {#sec6-biomolecules-09-00834}
==========

Multiple linear regression analyses revealed that in our sample smoking and BMI were not significantly associated with majority of N-glycans in plasma (*p* \> 0.05) or IgG (*p* \> 0.05). However, as expected, there was a strong association of N-glycans with age, and therefore all glycan values were corrected for age ([Supplementary Tables S3 and S4](#app1-biomolecules-09-00834){ref-type="app"}). The analysis of the entire glycome included 39 N-glycans in plasma ([Table 1](#biomolecules-09-00834-t001){ref-type="table"}, [Supplementary Figure S1](#app1-biomolecules-09-00834){ref-type="app"}) and 24 IgG N-glycans ([Table 2](#biomolecules-09-00834-t002){ref-type="table"}, [Supplementary Figure S2](#app1-biomolecules-09-00834){ref-type="app"}).

6.1. N-glycans in Plasma {#sec6dot1-biomolecules-09-00834}
------------------------

Major glycan peak structures are described in [Supplementary Tables S1 and S2](#app1-biomolecules-09-00834){ref-type="app"}. To confirm changes in N-glycan levels in cases/controls, only significantly different N-glycan levels identified in both the discovery and replication cohorts, and altered in the same direction, were designated as significant. In the discovery cohort, comprised of 160 PTSD and 73 age-matched control subjects, 19 out of 39 plasma N-glycans were significantly different between subjects with PTSD and control subjects. In the replication cohort, comprised of 139 PTSD and 171 age-matched control subjects, only six plasma N-glycans out of 19 from the discovery study were confirmed to differ significantly between cases/controls ([Table 1](#biomolecules-09-00834-t001){ref-type="table"}). Among these six plasma N-glycans, four (GP14 = A2G2S1, GP27 = A3G3S3, GP33 = A4G4S3, GP39 = A4F1G4S4) were significantly higher, whereas two (GP16 = FA2G2S1, GP19 = M9) were significantly lower in PTSD subjects compared to controls in both cohorts ([Figure 1](#biomolecules-09-00834-f001){ref-type="fig"}). These results suggested that these six plasma N-glycans might be used as biomarkers of PTSD.

6.2. N-glycans Attached to IgG {#sec6dot2-biomolecules-09-00834}
------------------------------

Only 2 N-glycans bound to IgG (GP6 = FA2B, GP23 = FA2G2S2) differed significantly between individuals with PTSD and healthy subjects in the discovery cohort, but these findings were not confirmed in the replication study ([Table 2](#biomolecules-09-00834-t002){ref-type="table"}). These results revealed that N-glycans bound to IgG are not associated with PTSD.

6.3. GlycoAge Test {#sec6dot3-biomolecules-09-00834}
------------------

To evaluate whether N-glycans can be used as indicators of the accelerated aging in subjects with PTSD \[[@B19-biomolecules-09-00834]\], a GlycoAge test was calculated for cases/controls in the discovery/replication study ([Table 1](#biomolecules-09-00834-t001){ref-type="table"}; [Table 2](#biomolecules-09-00834-t002){ref-type="table"}). There were no significant differences between individuals with PTSD and control subjects in the GlycoAge values in the discovery study for plasma (*p* = 0.208) and IgG N-glycans (*p* = 0.067). These findings were confirmed in the replication study as both plasma (*p* = 0.489) and IgG (*p* = 0.778) GlycoAge values did not differ significantly between participants with PTSD or control participants.

6.4. N-glycans and PTSD Severity {#sec6dot4-biomolecules-09-00834}
--------------------------------

As plasma N-glycans differed significantly between cases and controls, we assessed the possible association between plasma N-glycans and PTSD severity using the Spearman's correlation ([Table 3](#biomolecules-09-00834-t003){ref-type="table"}).

In our sample, most of the patients with PTSD had moderate symptoms (92% in both cohorts), whereas the remainder were diagnosed with severe PTSD. No significant correlations were detected between any of the plasma N-glycans and severity of PTSD in discovery or replication cohort ([Table 3](#biomolecules-09-00834-t003){ref-type="table"}). Additionally, differences in plasma N-glycans between patients with moderate and severe PTSD, evaluated with Mann--Whitney U test, were not significant. These results confirmed the lack of association between plasma glycosylation and severity of PTSD symptoms ([Table 3](#biomolecules-09-00834-t003){ref-type="table"}).

Furthermore, individuals with moderate and severe PTSD had similar GlycoAge values in the discovery (*p* = 0.984) and replication cohort (*p* = 0.969) ([Table 3](#biomolecules-09-00834-t003){ref-type="table"}). These results revealed that PTSD severity was not associated with GlycoAge index in individuals with PTSD.

7. Discussion {#sec7-biomolecules-09-00834}
=============

7.1. N-glycans in Plasma {#sec7dot1-biomolecules-09-00834}
------------------------

This is the first study to show significant associations of the plasma, but not IgG, N-glycans with combat-related PTSD. These results, confirmed in both discovery and replication study, have shown in a fairly large sample size, that four plasma N-glycans (A2G2S1, A3G3S3, A4G4S4, A4F1G4S4) were increased, whereas two plasma glycan species (FA2G2S1, M9) were decreased in individuals with PTSD compared to control subjects. Furthermore, individuals with PTSD did not show signs of accelerated physiological aging compared to healthy control subjects, determined with GlycoAge Test index \[[@B14-biomolecules-09-00834],[@B19-biomolecules-09-00834]\]. Additionally, severity of PTSD was not associated with plasma N-glycans.

Although several studies have analyzed N-glycosylation profiles in psychiatric and neurodegenerative diseases \[[@B31-biomolecules-09-00834]\]; Moreno-Villanueva's study \[[@B19-biomolecules-09-00834]\] was the only one that analyzed these changes in PTSD subjects. Their study \[[@B19-biomolecules-09-00834]\] focused on nine N-glycan structures in plasma of 32 individuals: 13 medicated subjects with PTSD, comorbid with MDD, nine trauma-exposed individuals and 10 low-stress control subjects of different ethnicities. In contrast to our results, they found no significant differences in plasma N-glycans between these groups \[[@B19-biomolecules-09-00834]\]. However, our study analyzed N-glycosylation profile (39 N-glycan species in plasma and 24 attached to IgG) on a much larger and homogenous sample (*N* = 543) of medication-free males (PTSD/controls), without MDD or other comorbidities.

As N-glycosylation is associated with accelerated aging, a GlycoAge Test has been proposed to predict physiological aging in healthy populations \[[@B14-biomolecules-09-00834]\]. Higher GlycoAge values have been reported in individuals with AD \[[@B14-biomolecules-09-00834]\] and PTSD \[[@B19-biomolecules-09-00834]\], when compared to healthy controls matched for age. Although there was a significant association of GlycoAge values with chronological age in both PTSD and control subjects in our study, there were no significant differences in its values between PTSD/controls, after correcting for age and multiple testing in the large sample of male Caucasian veterans with PTSD. Further modeling of GlycoAge test formula with other identified N-glycan species, obtained in our study, due to more precise separation, and possibly inclusion of additional biochemical and metabolic parameters \[[@B32-biomolecules-09-00834]\], could yield more accurate results.

Plasma N-glycan profile in PTSD patients from both cohorts was characterized by a greater abundance of highly branched (tri-antennary and tetra-antennary) structures, that were more galactosylated and sialylated (A3G3S3, A4G4S4, and A4F1G4S4). This pattern is identified in acute and chronic inflammation states \[[@B33-biomolecules-09-00834]\], and in patients 24--48 h after abdominal surgery \[[@B34-biomolecules-09-00834]\]. Increased highly sialyated and glycosylated N-glycan species (A3F1G3S3 and A4G4LacS4 in low abundant proteins, and A3F1G3S3, A4G4S2, A4G4S3, FA3G3S3, and FA3BG3S3 in highly abundant proteins) were detected in sera of male schizophrenic subjects \[[@B15-biomolecules-09-00834]\]. Patients with PTSD often exhibit psychotic symptoms \[[@B35-biomolecules-09-00834]\] that are hallmarks of schizophrenia. Therefore, a similar N-glycosylation profile in these two disorders is not unexpected. A3F1G3S3 N-glycan containing a sLe^x^ epitope, that is associated with increased immunological reaction to antigens \[[@B36-biomolecules-09-00834]\] and metastasis \[[@B37-biomolecules-09-00834]\], was significantly increased in both low and high abundant proteins \[[@B15-biomolecules-09-00834]\]. In our study, A4F1G4S4 N-glycan, that also contains sLe^x^ epitope, was significantly increased in both cohorts, similarly to results in the recently operated patients \[[@B34-biomolecules-09-00834]\]. Increased glycan branching in total plasma proteins, detected in our veterans with PTSD has previously been found to positively correlate with severity of MDD \[[@B16-biomolecules-09-00834]\], a common comorbidity in patients with PTSD. Although our veterans did not have clinical MDD, they share some common depressive/numbing symptoms and similar N-glycan changes. In contrast to the results of present study, increased peripheral fucosylation of biantennary glycans and decreased branching, including tri- and tetraantennary glycans, was detected in ADHD in our previous study \[[@B17-biomolecules-09-00834]\]. These differences might be explained with different diagnoses (ADHD vs. PTSD), differences in gender and age (average 9-year-old male and female children with ADHD vs. 54-year-old male veterans with PTSD and control male participants).

In our study, high-mannose (M9) and core-fucosylated (FA2G2S1) plasma glycan species were significantly decreased in the PTSD group, compared to the low-stress healthy control, and this result corresponds to lower glycan species found in inflammation \[[@B34-biomolecules-09-00834]\]. As alternations of high-mannose glycans have been associated with occurrence and progression of different types of cancers \[[@B38-biomolecules-09-00834],[@B39-biomolecules-09-00834],[@B40-biomolecules-09-00834]\], neuropsychiatric disorders \[[@B41-biomolecules-09-00834]\], inflammation \[[@B34-biomolecules-09-00834]\] and brain aging \[[@B42-biomolecules-09-00834]\], whereas PTSD is associated with inflammation \[[@B17-biomolecules-09-00834]\] and cardiometabolic disorders \[[@B4-biomolecules-09-00834],[@B5-biomolecules-09-00834]\], the lower FA2G2S1 glycan result suggests that veterans with PTSD should be closely monitored for these disorders.

Traumatic load was reported to be positively correlated with the GlycoAge Test in subjects with substantial trauma exposure \[[@B19-biomolecules-09-00834]\]. In our study, severity of PTSD was not significantly associated with plasma N-glycans. This could be explained by the fact that our study included PTSD patients with similar trauma experience and duration, and the fact that 92% of our patients had moderate symptoms of PTSD in both cohorts.

7.2. N-glycans Attached to IgG {#sec7dot2-biomolecules-09-00834}
------------------------------

We found two IgG glycoforms to be significantly different between PTSD and control subjects in the first cohort. Core fucosylated bisecting agalactosylated N-glycan FA2B was significantly increased in patients with PTSD, while more sialyated and galactosylated form, FA2G2S2, was significantly lower. Core fucosylated N-glycans on IgG are generally considered anti-inflammatory as core fucosylation of IgG can drastically increase antibody-dependent cytotoxicity \[[@B43-biomolecules-09-00834]\], while decreased galactosylation containing bisecting GlcNAC on IgG is usually hallmark of inflammation and older age \[[@B32-biomolecules-09-00834]\]. However, the replication cohort did not confirm these changes in FA2B and FA2G2S2 after correcting for multiple testing. Previous research in IgG N-glycome of patients with MDD (male and female combined) has found only two significant glycoforms, both containing bisecting GlcNAC, but similar to our results, there were no significant correlations when males were analyzed separately \[[@B16-biomolecules-09-00834]\].

8. Conclusions {#sec8-biomolecules-09-00834}
==============

We selected two large and balanced cohorts in order to identify potential alterations in N-glycosylation pattern characteristic for PTSD. Strength of the study is in a relatively homogeneous sample of age- and sex-matched PTSD patients and controls, with strict exclusion criteria. To ensure that our findings are due to a true biological variation, and to eliminate any possible experimental artefacts and false positive findings due to chance, we replicated our results using a second cohort. Besides, the study analyzed both plasma and IgG N-glycosylation with high-resolution separation techniques and reported only the results that were significant in both discovery and replication cohort, after adjustment for age and multiple testing. To avoid possible bias, plasma samples in both cohorts were randomized and blinded prior to N-glycan determination. However, we still detected differences between discovery and replication cohort that we cannot yet explain, possibly due to other biological parameters or unknown confounders that we did not take into account during sampling and/or statistical analysis.

Limitation of this study is in a relatively narrow subpopulation of patients of the same ethnicity, gender and type of trauma. To validate obtained results, inclusion of women, different ethnicities, individuals exposed to different types of trauma, as well as trauma-exposed controls without PTSD is necessary.

In conclusion, this is the first study detecting alterations in the selected plasma N-glycans in PTSD. Our results suggest that PTSD share similar biological underpinning as other neuropsychiatric disorders and inflammation and could point out to some common glycosylation mechanisms underlying neuropsychiatric disorders and inflammation.

We are extremely grateful to all the subjects who took part in this study.

The following are available online at <https://www.mdpi.com/2218-273X/9/12/834/s1>, Figure S1: Representative chromatogram of plasma N-glycans, Figure S2: Representative chromatogram of IgG N-glycans, Table S1: Plasma N-glycan peaks separated by HILIC-UPLC and their composition as described by Gudelj et al. (2016), Table S2: IgG N-glycan peaks separated by HILIC-UPLC and their composition as described by Nikolac Perkovic et al. (2016), Table S3: Effects of age, smoking and BMI on plasma N-glycan species in the discovery and replication cohort, Table S4. Effects of age, smoking and BMI on plasma N-glycan species in the discovery and replication cohort.
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###### 

Distribution of total plasma N-glycans in healthy controls and patients with PTSD in discovery and replication cohort. Results are presented as age adjusted percentage of total glycan peak area (median, 25th, and 75th percentile).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Plasma\     Discovery Cohort (*N* = 233)   Replication Cohort (*N* = 330)                                                                                                                              
  N-glycan\                                                                                                                                                                                              
  Peak                                                                                                                                                                                                   
  ----------- ------------------------------ -------------------------------- -------- -------- -------- -------- -------- ------------- -------- -------- -------- -------- -------- -------- --------- -----------
  GP1         4.615                          3.885                            5.514    4.161    3.392    5.103    4810.0   0.062         5.457    4.454    6.559    5.895    4.568    6.843    11094.0   0.524

  GP2         1.994                          1.740                            2.267    1.970    1.726    2.261    5630.0   0.777         2.168    1.911    2.449    2.237    1.901    2.510    11476.0   0.719

  GP3         0.084                          0.071                            0.101    0.089    0.068    0.109    5448.0   0.515         0.103    0.083    0.125    0.106    0.087    0.132    11490.0   0.719

  GP4         3.759                          3.232                            4.411    3.234    2.867    3.711    3783.0   **\<0.001**   3.770    3.178    4.426    3.666    3.183    4.308    11793.0   0.908

  GP5         2.062                          1.658                            2.394    1.684    1.394    1.971    3475.0   **\<0.001**   2.085    1.645    2.570    1.961    1.617    2.393    10989.0   0.484

  GP6         1.212                          1.048                            1.387    1.157    1.025    1.341    5085.0   0.182         1.336    1.162    1.503    1.336    1.131    1.506    11633.0   0.810

  GP7         1.023                          0.960                            1.124    0.979    0.902    1.144    5235.0   0.304         1.059    0.945    1.180    0.991    0.885    1.110    9285.0    **0.014**

  GP8         1.046                          0.993                            1.134    1.088    0.974    1.189    5260.0   0.310         1.047    0.964    1.173    1.113    1.017    1.246    9453.0    **0.016**

  GP9         0.098                          0.087                            0.112    0.099    0.083    0.113    5827.0   0.986         0.111    0.095    0.127    0.109    0.092    0.126    11156.0   0.545

  GP10        3.345                          2.983                            4.145    2.809    2.313    3.501    3820.0   **\<0.001**   3.157    2.529    3.822    3.064    2.511    3.573    11242.0   0.612

  GP11        0.701                          0.641                            0.880    0.701    0.590    0.840    5516.0   0.603         0.820    0.710    0.939    0.757    0.654    0.894    9913.0    **0.043**

  GP12        0.998                          0.939                            1.062    1.022    0.905    1.105    5414.0   0.481         1.005    0.927    1.089    0.972    0.885    1.070    10629.0   0.278

  GP13        0.710                          0.627                            0.875    0.655    0.559    0.761    4210.0   **0.002**     0.801    0.683    0.943    0.775    0.626    0.933    11038.0   0.489

  GP14        12.136                         11.145                           12.590   12.476   11.790   13.067   4261.0   **0.003**     11.478   10.904   12.237   11.823   11.177   12.529   9652.0    **0.025**

  GP15        0.396                          0.349                            0.451    0.443    0.377    0.509    4278.0   **0.003**     0.518    0.448    0.582    0.474    0.427    0.546    9919.0    **0.043**

  GP16        4.716                          4.240                            5.276    4.262    3.813    4.843    4080.0   **0.001**     4.807    4.236    5.467    4.594    4.028    5.060    9813.0    **0.038**

  GP17        1.652                          1.480                            1.977    1.779    1.410    2.272    5254.0   0.310         2.063    1.763    2.404    1.844    1.598    2.224    9375.0    **0.014**

  GP18        3.714                          3.174                            4.006    3.363    3.073    3.765    4873.0   0.082         3.158    2.865    3.495    3.144    2.900    3.619    11353.0   0.712

  GP19        0.957                          0.873                            1.051    0.902    0.829    0.982    4627.0   **0.023**     0.974    0.869    1.030    0.902    0.828    0.991    8778.0    **0.003**

  GP20        29.128                         27.579                           30.740   29.152   27.525   30.769   5657.0   0.802         26.692   24.870   27.838   26.487   24.682   28.160   11505.0   0.719

  GP21        0.510                          0.466                            0.544    0.513    0.468    0.545    5391.0   0.463         0.616    0.560    0.664    0.612    0.557    0.662    11575.0   0.771

  GP22        4.243                          3.813                            4.699    3.859    3.422    4.258    4089.0   **0.001**     4.001    3.607    4.529    3.936    3.459    4.572    10881.0   0.403

  GP23        2.009                          1.585                            2.420    2.029    1.545    2.372    5687.0   0.833         2.281    1.930    2.751    2.163    1.805    2.632    10772.0   0.360

  GP24        1.383                          1.240                            1.725    1.532    1.232    1.814    5061.0   0.171         1.432    1.130    1.693    1.442    1.191    1.739    11457.0   0.719

  GP25        0.292                          0.269                            0.316    0.294    0.270    0.319    5717.0   0.839         0.274    0.252    0.299    0.279    0.247    0.305    11409.0   0.719

  GP26        1.434                          1.340                            1.731    1.621    1.402    1.836    4590.0   **0.020**     1.534    1.322    1.720    1.499    1.275    1.683    10634.0   0.278

  GP27        0.690                          0.528                            0.891    0.884    0.662    1.084    4160.0   **0.002**     0.946    0.734    1.117    1.075    0.853    1.263    9374.0    **0.014**

  GP28        0.683                          0.589                            0.767    0.672    0.551    0.795    5831.0   0.986         0.636    0.520    0.736    0.604    0.508    0.739    11157.0   0.545

  GP29        0.201                          0.170                            0.231    0.184    0.158    0.220    4975.0   0.127         0.181    0.154    0.201    0.172    0.155    0.203    11454.0   0.719

  GP30        4.684                          4.279                            5.584    5.210    4.170    5.869    5029.0   0.156         4.826    3.944    5.490    4.602    3.892    5.347    10852.0   0.397

  GP31        0.425                          0.358                            0.523    0.430    0.339    0.525    5703.0   0.838         0.433    0.350    0.531    0.395    0.320    0.478    9931.0    **0.043**

  GP32        1.503                          1.199                            1.730    1.774    1.468    2.045    3733.0   **\<0.001**   1.598    1.344    1.846    1.594    1.315    1.894    11696.0   0.848

  GP33        2.807                          2.083                            3.490    3.523    2.781    4.361    3883.0   **\<0.001**   3.504    2.766    4.213    4.049    3.165    4.728    9528.0    **0.018**

  GP34        0.347                          0.310                            0.409    0.395    0.342    0.445    4210.0   **0.002**     0.385    0.340    0.454    0.384    0.347    0.434    11482.0   0.719

  GP35        0.352                          0.261                            0.460    0.424    0.335    0.546    4287.0   **0.003**     0.417    0.346    0.518    0.454    0.369    0.566    10481.0   0.211

  GP36        0.488                          0.429                            0.549    0.603    0.547    0.690    2393.0   **\<0.001**   0.557    0.485    0.627    0.593    0.515    0.651    10436.0   0.200

  GP37        0.412                          0.349                            0.473    0.465    0.371    0.568    4533.0   **0.015**     0.452    0.385    0.553    0.462    0.389    0.546    11712.0   0.848

  GP38        0.890                          0.737                            1.013    1.067    0.936    1.258    3029.0   **\<0.001**   1.038    0.923    1.222    1.098    0.985    1.234    10786.0   0.360

  GP39        0.783                          0.645                            0.920    1.062    0.856    1.300    2931.0   **\<0.001**   1.000    0.826    1.318    1.133    0.974    1.481    9822.0    **0.038**

  GlycoAge    0.112                          0.017                            0.238    0.163    0.040    0.295    5126.0   0.208         0.219    0.128    0.384    0.256    0.145    0.394    11021.0   0.489
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results of the statistics are denoted as Mann Whitney U value (MW U) and false discovery rate (FDR) adjusted *p* value (*p*), where significant results are shown in bold. GP = glycan peak; GlycoAge index = log 10(FA2/FA2G2); PTSD = post-traumatic stress disorder.

biomolecules-09-00834-t002_Table 2

###### 

Distribution of N-glycan structures on IgG in healthy controls and patients with PTSD in discovery and replication cohort. Results are presented as age adjusted percentage of total glycan peak area (median, 25th, and 75th percentile).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  IgG\        Discovery cohort (*N* = 233)   Replication cohort (*N* = 330)                                                                                                                            
  N-glycan\                                                                                                                                                                                            
  Peak                                                                                                                                                                                                 
  ----------- ------------------------------ -------------------------------- -------- -------- -------- -------- -------- ----------- -------- -------- -------- -------- -------- -------- --------- -------
  GP1         0.085                          0.070                            0.111    0.089    0.072    0.110    5668.0   0.889       0.097    0.080    0.114    0.100    0.081    0.124    11164.0   0.778

  GP2         0.536                          0.368                            0.719    0.642    0.399    0.924    4887.0   0.170       0.739    0.515    1.001    0.710    0.493    1.111    11671.0   0.987

  GP3         0.104                          0.088                            0.116    0.108    0.091    0.125    5009.0   0.288       0.123    0.111    0.141    0.125    0.110    0.140    11811.0   0.987

  GP4         21.850                         17.974                           25.144   22.733   19.818   27.247   4905.0   0.218       24.042   21.203   28.427   25.366   21.501   29.433   10892.0   0.778

  GP5         0.163                          0.150                            0.178    0.157    0.142    0.174    5214.0   0.218       0.184    0.157    0.209    0.183    0.153    0.214    11700.0   0.894

  GP6         5.340                          4.262                            6.201    6.167    5.056    7.334    4046.0   **0.012**   6.036    4.952    7.274    6.253    5.229    7.436    11067.0   0.778

  GP7         0.365                          0.289                            0.450    0.402    0.274    0.531    5495.0   0.551       0.452    0.333    0.562    0.442    0.354    0.597    11456.0   0.833

  GP8         18.936                         17.695                           19.801   18.551   17.409   19.584   5297.0   0.428       18.179   16.802   19.415   18.129   17.002   19.232   11641.0   0.833

  GP9         9.594                          8.789                            10.605   9.142    8.198    10.011   4672.0   0.061       9.593    8.564    10.422   9.241    8.488    10.050   10592.0   0.778

  GP10        4.910                          4.291                            5.618    5.172    4.574    6.129    4688.0   0.067       5.083    4.405    5.728    5.134    4.342    6.037    11427.0   0.833

  GP11        0.670                          0.578                            0.732    0.708    0.638    0.821    4489.0   0.061       0.683    0.612    0.756    0.678    0.593    0.765    11853.0   0.987

  GP12        0.684                          0.544                            0.895    0.643    0.466    0.928    5521.0   0.730       0.607    0.456    0.923    0.615    0.477    0.966    11571.0   0.833

  GP13        0.264                          0.230                            0.298    0.258    0.229    0.293    5688.0   0.885       0.261    0.228    0.297    0.257    0.225    0.300    11484.0   0.833

  GP14        13.171                         11.025                           15.405   11.864   9.800    13.913   4284.0   0.051       11.689   8.929    13.593   11.015   8.708    12.681   11005.0   0.778

  GP15        1.762                          1.595                            1.919    1.736    1.482    1.960    5570.0   0.885       1.651    1.445    1.861    1.639    1.438    1.849    11831.0   0.987

  GP16        3.126                          2.837                            3.437    3.086    2.768    3.393    5539.0   0.430       3.086    2.838    3.429    3.071    2.739    3.406    11222.0   0.778

  GP17        0.973                          0.917                            1.088    0.967    0.881    1.110    5638.0   0.885       1.008    0.878    1.125    0.986    0.882    1.119    11677.0   0.833

  GP18        9.359                          7.857                            10.641   8.559    6.916    9.896    4443.0   0.061       7.824    6.701    9.282    7.705    6.738    8.886    11115.0   0.778

  GP19        1.992                          1.749                            2.206    2.010    1.752    2.314    5461.0   0.612       1.966    1.762    2.259    1.952    1.602    2.207    10479.0   0.373

  GP20        0.419                          0.373                            0.471    0.428    0.380    0.472    5837.0   0.885       0.404    0.362    0.460    0.398    0.353    0.455    11154.0   0.778

  GP21        0.851                          0.783                            0.942    0.875    0.792    0.972    5459.0   0.430       0.908    0.834    1.003    0.874    0.802    0.958    9792.0    0.174

  GP22        0.165                          0.132                            0.201    0.173    0.143    0.210    5273.0   0.327       0.148    0.122    0.182    0.146    0.120    0.178    11278.0   0.778

  GP23        1.790                          1.508                            2.226    1.587    1.340    1.888    4307.0   **0.025**   1.615    1.426    2.035    1.623    1.303    1.847    10358.0   0.373

  GP24        1.816                          1.637                            2.070    1.939    1.669    2.253    5011.0   0.259       1.960    1.735    2.229    1.865    1.559    2.241    10417.0   0.373

  Glycoage    0.211                          0.053                            0.335    0.283    0.155    0.446    4735.0   0.067       0.313    0.207    0.521    0.354    0.245    0.520    11271.0   0.778
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results of the statistics are denoted as Mann Whitney U value (MW U) and adjusted *p*-value (false discovery rate (FDR) method). GP = glycan peak; GlycoAge index = log 10(FA2/FA2G2); PTSD: post-traumatic stress disorder.

biomolecules-09-00834-t003_Table 3

###### 

Correlation between PTSD severity determined by the CAPS scores and distribution of total plasma N-glycan structures, as well as differences between veterans with moderate and severe PTSD in discovery and replication cohort.

  Plasma N-Glycan Peak   Discovery Cohort (*N* = 233)   Replication Cohort (*N* = 330)                                           
  ---------------------- ------------------------------ -------------------------------- ------- ------- ------- ------- ------- -------
  GP1                    0.035                          0.791                            875.0   0.984   0.076   0.991   612.0   0.921
  GP2                    0.031                          0.801                            885.0   0.984   0.009   0.991   644.0   0.921
  GP3                    0.126                          0.364                            804.0   0.899   0.078   0.991   562.0   0.921
  GP4                    0.139                          0.330                            821.0   0.899   0.003   0.991   615.0   0.921
  GP5                    0.149                          0.330                            815.0   0.899   0.034   0.991   576.0   0.921
  GP6                    0.104                          0.388                            741.0   0.829   0.076   0.991   683.0   0.969
  GP7                    0.095                          0.395                            753.0   0.829   0.119   0.991   687.0   0.969
  GP8                    0.026                          0.826                            693.0   0.829   0.009   0.991   649.0   0.921
  GP9                    0.111                          0.388                            816.0   0.899   0.037   0.991   668.0   0.969
  GP10                   0.110                          0.388                            877.0   0.984   0.017   0.991   635.0   0.921
  GP11                   0.055                          0.735                            686.0   0.829   0.060   0.991   699.0   0.969
  GP12                   0.013                          0.904                            680.0   0.829   0.020   0.991   648.0   0.921
  GP13                   0.110                          0.388                            839.0   0.969   0.020   0.991   508.0   0.921
  GP14                   0.047                          0.773                            678.0   0.829   0.005   0.991   570.0   0.921
  GP15                   0.100                          0.388                            817.0   0.899   0.014   0.991   525.0   0.921
  GP16                   0.100                          0.388                            770.0   0.829   0.012   0.991   544.0   0.921
  GP17                   0.044                          0.784                            735.0   0.829   0.018   0.991   641.0   0.921
  GP18                   0.041                          0.791                            745.0   0.829   0.001   0.991   685.0   0.969
  GP19                   0.148                          0.330                            602.0   0.829   0.204   0.312   593.0   0.921
  GP20                   0.118                          0.388                            798.0   0.899   0.004   0.991   605.0   0.921
  GP21                   0.034                          0.791                            881.0   0.984   0.092   0.991   625.0   0.921
  GP22                   0.095                          0.395                            845.0   0.976   0.029   0.991   605.0   0.921
  GP23                   0.012                          0.904                            850.0   0.977   0.097   0.991   514.0   0.921
  GP24                   0.137                          0.330                            823.0   0.899   0.025   0.991   696.0   0.969
  GP25                   0.034                          0.791                            635.0   0.829   0.205   0.312   505.0   0.921
  GP26                   0.048                          0.773                            685.0   0.829   0.070   0.991   586.0   0.921
  GP27                   0.136                          0.330                            725.0   0.829   0.064   0.991   452.0   0.921
  GP28                   0.170                          0.330                            736.0   0.829   0.012   0.991   676.0   0.969
  GP29                   0.009                          0.914                            770.0   0.829   0.058   0.991   672.0   0.969
  GP30                   0.133                          0.330                            621.0   0.829   0.018   0.991   693.0   0.969
  GP31                   0.158                          0.330                            668.0   0.829   0.117   0.991   641.0   0.921
  GP32                   0.104                          0.388                            872.0   0.984   0.008   0.991   602.0   0.921
  GP33                   0.146                          0.330                            760.0   0.829   0.011   0.991   508.0   0.921
  GP34                   0.017                          0.901                            752.0   0.829   0.134   0.991   590.0   0.921
  GP35                   0.106                          0.388                            773.0   0.829   0.038   0.991   515.0   0.921
  GP36                   0.136                          0.330                            867.0   0.984   0.093   0.991   580.0   0.921
  GP37                   0.056                          0.735                            696.0   0.829   0.002   0.991   614.0   0.921
  GP38                   0.074                          0.575                            772.0   0.829   0.028   0.991   695.0   0.969
  GP39                   0.151                          0.330                            806.0   0.899   0.025   0.991   628.0   0.921
  GlycoAge               0.036                          0.791                            875.0   0.984   0.013   0.991   689.0   0.969

Results of the statistics are denoted as Spearman's rho coefficient (ρ), Mann Whitney U value (MW U), and corresponding adjusted *p* value (false discovery rate (FDR) method). GP = glycan peak; GlycoAge index = log10 (FA2/FA2G2); PTSD = post-traumatic stress disorder.
